CME/CE INFORMATION

Rural Health Clinical Congress Fall 2022

Saturday, November 19, 2022 | Virtual Live CME/CE Conference
Broadcast starts at 8:00 AM CT


HOW TO CLAIM CREDIT
In order to obtain your CME/CE certificate(s), please follow the steps below at the conclusion of the event:

  • Step 1: Log In
    Access the event here. At the upper right corner, click Login and enter your username (the email address you used to register for the event) and password.
    If you do not know your password, follow the link to reset it.
  • Step 2: Complete Evaluation(s)
    Click the Evaluations tab on the left. You will see a listing of each session. Click the blue Take Evaluation button and complete the evaluation form for each session you attended.
  • Step 3: View and Print Certificate(s)
    After you’ve completed the evaluation(s), click the blue Print Certificate button to view and print your CME/CE certificate(s).




Optimizing Outcomes of Moderate-to-Severe Asthma in Rural 
and Underserved Settings:
A Personalized Approach


Jointly provided by Postgraduate Institute for Medicine and RME Collaborative:

custom image

TARGET AUDIENCE
This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.

LEARNING OBJECTIVES

  • Apply current guidelines and recommendations for the management of patients with moderate-to-severe asthma to clinical practice
  • Identify appropriate therapy for patients with moderate-to-severe asthma based on patient preferences, phenotypes, and comorbid conditions
  • Utilize strategies for improving asthma care and management in rural and underserved settings, including self-management education and asthma action plans

FACULTY
Autumn Burnette, MD, FACAAI
Assistant Professor
Division of Allergy and Immunology
Howard University Hospital
Washington, DC

Barbara P. Yawn, MD, MSc, FAAFP
Professor of Family and Community Health
University of Minnesota
Minneapolis, MN

JOINT ACCREDITATION STATEMENT

custom image

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine and RME Collaborative adhere to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Postgraduate Institute for Medicine requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies (commercial interests). All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to Postgraduate Institute for Medicine policy. Postgraduate Institute for Medicine is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Autumn Burnette, MD, FACAAI, has disclosed the following relevant financial relationships: consultant/advisory board for AbbVie, Inc., AstraZeneca and Amgen, Inc., BioCryst Pharmaceuticals, Inc., Cycle Pharmaceuticals, GSK, KalVista Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc. and Sanofi, and Takeda Pharmaceuticals U.S.A., Inc.; and speakers’ bureau/honoraria from AbbVie, Inc., ACK, AstraZeneca and Amgen, Biocryst, CSL Bettring, GSK, Pfizer, Inc., Pharming, Sanofi and Regeneron, and Takeda Pharmaceuticals U.S.A., Inc.

Barbara P. Yawn, MD, MSc, FAAFP, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer
The Postgraduate Institute for Medicine and RME Collaborative planners, managers, and reviewer have nothing to disclose.

ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Astellas; Eisai, Inc.; Genentech, a member of the Roche Group; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Organon & Co.; Pfizer, Inc.; and Regeneron Pharmaceuticals, Inc. and Sanofi.

This session is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT US
General Questions
For general information or questions about this activity, please contact RME Collaborative at 800-913-9370 or cme@cmeruralhealth.com.

Accreditation Support
For questions regarding the certification of this activity, please contact Postgraduate Institute for Medicine at inquiries@pimed.com.


Addressing the Burden of Chronic Rhinosinusitis With Nasal Polyps:
Strategies for Managing Patients in Rural and Underserved Communities


Jointly provided by Postgraduate Institute for Medicine and RME Collaborative:

custom image

TARGET AUDIENCE
This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.

LEARNING OBJECTIVES

  • Describe the pathophysiology and biological mechanisms involved in chronic rhinosinusitis with nasal polyps
  • Summarize the efficacy and safety data of new and emerging biologic treatment options for chronic rhinosinusitis with nasal polyps
  • Identify appropriate patients with chronic rhinosinusitis with nasal polyps for biologic therapy
  • Utilize strategies for improving multidisciplinary care and management of chronic rhinosinusitis with nasal polyps in rural and underserved populations

FACULTY
Stella Lee, MD
Associate Surgeon
Harvard Medical School
Section Chief – Rhinology
Brigham and Women’s Hospital
Boston, MA

Barbara P. Yawn, MD, MSc, FAAFP
Professor of Family and Community Health
University of Minnesota
Minneapolis, MN

JOINT ACCREDITATION STATEMENT

custom image

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Designated for 0.25 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine and RME Collaborative adhere to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Postgraduate Institute for Medicine requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies (commercial interests). All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to Postgraduate Institute for Medicine policy. Postgraduate Institute for Medicine is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Stella Lee, MD, has disclosed the following relevant financial relationships: consultant/advisory board for Regeneron Pharmaceuticals, Inc. and Sanofi; and Genzyme.

Barbara P. Yawn, MD, MSc, FAAFP, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer
The Postgraduate Institute for Medicine and RME Collaborative planners, managers, and reviewer have nothing to disclose.

ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Astellas; Eisai, Inc.; Genentech, a member of the Roche Group; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Organon & Co.; Pfizer, Inc.; and Regeneron Pharmaceuticals, Inc. and Sanofi.

This session is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT US
General Questions
For general information or questions about this activity, please contact RME Collaborative at 800-913-9370 or cme@cmeruralhealth.com.

Accreditation Support
For questions regarding the certification of this activity, please contact Postgraduate Institute for Medicine at inquiries@pimed.com.


Liver Cancer Screening and Management in Primary Care:
Early Detection to Improve Patient Outcomes in Rural and Underserved Communities


Provided by Talem Health:

custom image

TARGET AUDIENCE
This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.

LEARNING OBJECTIVES

  • Apply clinical guidelines for hepatocellular carcinoma (HCC) surveillance to clinical practice
  • Assess the safety and efficacy of available therapies for HCC to effectively counsel patients requiring HCC care
  • Discuss the role of multidisciplinary care in improving outcomes in patients with HCC

FACULTY
Ghassan K. Abou-Alfa, MD, MBA
Attending Physician
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell College at Cornell University
New York, NY

Barbara P. Yawn, MD, MSc, FAAFP
Professor of Family and Community Health
University of Minnesota
Minneapolis, MN

JOINT ACCREDITATION STATEMENT

custom image

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Designated for 0.25 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Ghassan K. Abou-Alfa, MD, MBA, has disclosed the following relevant financial relationships: research/grant support from Arcus Biosciences, AstraZeneca Pharmaceuticals, BioNTech, BMS, Celgene Corporation, Flatiron Health, Genentech, Inc./Roche, Genoscience Pharma, Incyte Corporation, Polaris Pharmaceuticals, Inc., Puma Biotechnology, Inc., QED Therapeutics, Silenseed, and Yiviva; consultant for Adicet Bio, Inc., Alnylam Pharmaceuticals, AstraZeneca Pharmaceuticals, Autem Therapeutics, BeiGene, Berry Genomics, Boehringer Ingelheim, Celgene Corporation, Cend Therapeutics, CytomX Therapeutics, Eisai, Inc., Eli Lilly and Company, Exelixis, Inc., Flatiron Health, Genentech, Inc./Roche, Genoscience Pharma, Helio Genomics, Helsinn Group, Incyte Corporation, Ipsen, Merck & Co., Inc., Nerviano Medical Sciences, NewBridge Pharmaceuticals, Novartis Pharmaceuticals Corporation, QED Therapeutics, RedHill Biopharma, Rafael Pharmaceuticals, Inc. (now Cornerstone Pharmaceuticals, Inc.), Servier Pharmaceuticals, Silenseed, Sobi, Vector Pharma, and Yiviva.

Barbara P. Yawn, MD, MSc, FAAFP, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Astellas; Eisai, Inc.; Genentech, a member of the Roche Group; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Organon & Co.; Pfizer, Inc.; and Regeneron Pharmaceuticals, Inc. and Sanofi.

This session is supported by independent medical education grants from Eisai, Inc. and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT US
For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.


Influenza Management Updates: Integrating Antiviral Treatment to
Improve Outcomes in Rural and Underserved Communities


Provided by Talem Health:

custom image

TARGET AUDIENCE
This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.

LEARNING OBJECTIVES

  • Identify candidates eligible for antiviral therapy based on their risk for influenza-related complications, in accordance with current guideline recommendations
  • Develop individualized antiviral treatment plans for patients with, or at risk for, influenza based on the latest clinical evidence
  • Employ multidisciplinary strategies to overcome challenges to treatment and prevention of influenza in rural and underserved communities

FACULTY
Richard A. Martinello, MD
Professor of Medicine (Infectious Diseases)
Yale School of Medicine
Medical Director of Infection Prevention
Yale New Haven Hospital & Yale New Haven Health
New Haven, CT

Barbara P. Yawn, MD, MSc, FAAFP
Professor of Family and Community Health
University of Minnesota
Minneapolis, MN

JOINT ACCREDITATION STATEMENT

custom image

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Richard A. Martinello, MD, has no relevant financial relationships to disclose.

Barbara P. Yawn, MD, MSc, FAAFP, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Astellas; Eisai, Inc.; Genentech, a member of the Roche Group; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Organon & Co.; Pfizer, Inc.; and Regeneron Pharmaceuticals, Inc. and Sanofi.

This session is supported by an independent medical education grant from Genentech, a member of the Roche Group.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT US
General Questions
For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.


Overcoming Disparities in Women's Reproductive Health:
The Role of Primary Care Clinicians in Rural and Underserved Communities


Provided by Talem Health:

custom image

TARGET AUDIENCE
This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.

LEARNING OBJECTIVES

  • Evaluate available interventions for family planning, including hormonal contraceptive options and infertility treatment options, for women living in rural and underserved communities
  • Apply current evidence and best practices for family planning, including hormonal contraceptive options and infertility treatment options, in women who reside in rural and underserved communities
  • Assess available treatment options for the management of postpartum hemorrhage
  • Integrate evidence-based strategies for improving access to care and reducing healthcare disparities among reproductive-aged women who reside in rural and underserved communities

FACULTY
Hugh S. Taylor, MD
Anita O'Keeffe Young Professor of Obstetrics, Gynecology, and Reproductive Sciences
Professor of Molecular, Cellular, and Developmental Biology
Chair of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine
Chief of Obstetrics and Gynecology, Yale-New Haven Hospital
New Haven, CT

Barbara P. Yawn, MD, MSc, FAAFP
Professor of Family and Community Health
University of Minnesota
Minneapolis, MN

JOINT ACCREDITATION STATEMENT

custom image

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Hugh S. Taylor, MD, has no relevant financial relationships to disclose.

Barbara P. Yawn, MD, MSc, FAAFP, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Astellas; Eisai, Inc.; Genentech, a member of the Roche Group; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Organon & Co.; Pfizer, Inc.; and Regeneron Pharmaceuticals, Inc. and Sanofi.

This session is supported by an independent medical education grant from Organon & Co.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT US
General Questions
For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.


Menopause and Mental Health: Strategies for Overcoming Barriers
and Advancing Health Equity in Rural and Underserved Communities


Jointly provided by Postgraduate Institute for Medicine and RME Collaborative:

custom image

TARGET AUDIENCE
This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.

LEARNING OBJECTIVES

  • Apply evidence-based strategies and recommendations to screen for depression and depressive symptoms in midlife women
  • Distinguish clinical manifestations of depressive disorders from menopausal symptoms and psychosocial distress during different stages of menopause
  • Develop personalized treatment plans for the management of depressive symptoms and major depressive episodes in midlife women who reside in rural and underserved communities

FACULTY
Hugh S. Taylor, MD
Anita O'Keeffe Young Professor of Obstetrics, Gynecology, and Reproductive Sciences
Professor of Molecular, Cellular, and Developmental Biology
Chair of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine
Chief of Obstetrics and Gynecology, Yale-New Haven Hospital
New Haven, CT

Barbara P. Yawn, MD, MSc, FAAFP
Professor of Family and Community Health
University of Minnesota
Minneapolis, MN

JOINT ACCREDITATION STATEMENT

custom image

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Pharmacotherapy contact hours for advanced practice registered nurses to be determined.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine and RME Collaborative adhere to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Postgraduate Institute for Medicine requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies (commercial interests). All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to Postgraduate Institute for Medicine policy. Postgraduate Institute for Medicine is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Hugh S. Taylor, MD,
has no relevant financial relationships to disclose.

Barbara P. Yawn, MD, MSc, FAAFP, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewers
The Postgraduate Institute for Medicine and RME Collaborative planners, managers, and reviewer have nothing to disclose.

ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Astellas; Eisai, Inc.; Genentech, a member of the Roche Group; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Organon & Co.; Pfizer, Inc.; and Regeneron Pharmaceuticals, Inc. and Sanofi.

This session is supported by independent medical education grants from Astellas and Pfizer, Inc.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT US
General Questions
For general information or questions about this activity, please contact RME Collaborative at 800-913-9370 or cme@cmeruralhealth.com.

Accreditation Support
For questions regarding the certification of this activity, please contact Postgraduate Institute for Medicine via email at inquiries@pimed.com.



OBTAINING CME/CE CREDIT
1. Register online
2. 
Attend the live program in its entirety
3. Complete an online program evaluation
4. Download and/or print a certificate of completion


MEDIA
Internet activity


COMPUTER SYSTEM REQUIREMENTS

  • System checker: Must meet all requirements of Digitell Live Events Platform
  • Operating system: Windows or Macintosh
  • Supported browsers: HTML5-capable browser – Internet Explorer, Google Chrome, Mozilla Firefox, Safari, Microsoft Edge, Opera
  • Hardware: computer, smartphone, or tablet
  • Broadband Internet connection: high-speed connection preferable

FEE INFORMATION
There is no fee for this educational activity
.

COPYRIGHT
©RME Collaborative, a division of Talem Health, LLC 2022. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.